share_log

BioVie | 8-K: Current report

BioVie | 8-K: Current report

BioVie | 8-K：重大事件
美股SEC公告 ·  2024/10/22 13:04

Moomoo AI 已提取核心信息

BioVie has completed its previously announced registered direct offering, raising gross proceeds of $6.66 million through the sale of 4,443,000 common shares at $1.50 per share. The company also conducted a concurrent private placement of warrants to purchase up to 4,443,000 shares at an exercise price of $1.37 per share. The total offering expenses were approximately $902,560.The warrants will become exercisable six months after issuance and will expire five years following the initial exercise date. The company plans to use the net proceeds primarily for working capital and general corporate purposes. ThinkEquity served as the sole placement agent for the offering.Following the offering, BioVie adjusted the exercise price of the existing Acuitas warrant from $1.53 to $1.37 per share, in accordance with the warrant's anti-dilution provisions. The Acuitas warrant, which expires on July 15, 2028, was previously issued under a Securities Purchase Agreement dated July 15, 2022.
BioVie has completed its previously announced registered direct offering, raising gross proceeds of $6.66 million through the sale of 4,443,000 common shares at $1.50 per share. The company also conducted a concurrent private placement of warrants to purchase up to 4,443,000 shares at an exercise price of $1.37 per share. The total offering expenses were approximately $902,560.The warrants will become exercisable six months after issuance and will expire five years following the initial exercise date. The company plans to use the net proceeds primarily for working capital and general corporate purposes. ThinkEquity served as the sole placement agent for the offering.Following the offering, BioVie adjusted the exercise price of the existing Acuitas warrant from $1.53 to $1.37 per share, in accordance with the warrant's anti-dilution provisions. The Acuitas warrant, which expires on July 15, 2028, was previously issued under a Securities Purchase Agreement dated July 15, 2022.
BioVie已完成之前宣布的注册直接发行，募集总收益为666万美元，通过以每股1.50美元的价格出售4,443,000股普通股。公司还同时进行了Warrants的定向增发，购买最多4,443,000股，执行价格为每股1.37美元。总发行费用约为902,560美元。这些Warrants将在发行六个月后可行使，并将在初始行使日期后五年到期。公司计划将净收益主要用于营运资金和一般企业用途。ThinkEquity担任本次发行的唯一安置代理。在发行后，BioVie根据Warrants的防稀释条款，将现有的Acuitas Warrants的行使价格从每股1.53美元调整至1.37美元。Acuitas Warrants将于2028年7月15日到期，之前是在2022年7月15日签署的证券购买协议下发行的。
BioVie已完成之前宣布的注册直接发行，募集总收益为666万美元，通过以每股1.50美元的价格出售4,443,000股普通股。公司还同时进行了Warrants的定向增发，购买最多4,443,000股，执行价格为每股1.37美元。总发行费用约为902,560美元。这些Warrants将在发行六个月后可行使，并将在初始行使日期后五年到期。公司计划将净收益主要用于营运资金和一般企业用途。ThinkEquity担任本次发行的唯一安置代理。在发行后，BioVie根据Warrants的防稀释条款，将现有的Acuitas Warrants的行使价格从每股1.53美元调整至1.37美元。Acuitas Warrants将于2028年7月15日到期，之前是在2022年7月15日签署的证券购买协议下发行的。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    TuHURA Biosciences
    HURA
    -- 3.850
    Aditxt
    ADTX
    -- 10.0300
    COSCIENS Biopharma
    CSCI
    -- 4.350
    Forte Biosciences
    FBRX
    -- 7.020
    Lyell Immunopharma
    LYEL
    -- 0.582
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    科技巨头财报季如火如荼，英伟达压轴会表现如何？
    星期四， $亚马逊 (AMZN.US)$ 股价在公司报告第四季度调整后每股收益为1.86美元，预估为每股1.50美元，营业收入为1877.9亿，预估为1873.2亿后下跌。该公司预测第一季度的营业收入数字低于华尔街的预期，预测本季度最多为1550亿，而分析师希望为1580亿。 星 展开
    亚马逊盈利预告：猜测开盘价，获取奖励！